This interventional trial (n=3) will assess the efficacy and safety of esketamine for the treatment of Rett Syndrome (RTT) in children aged 5 to 10 years.
This single-group interventional study will evaluate the efficacy and safety of intravenous esketamine (0.25 mg/kg) given weekly for five weeks in children aged 5–10 years with classic Rett syndrome caused by MECP2 mutation.
Participants receive five once-weekly 40-minute IV infusions (esketamine diluted in 20 ml saline). Outcomes include disease severity measures and safety assessments; stable seizure status is required at enrolment.
IV esketamine 0.25 mg/kg weekly for 5 weeks
Diluted in 20 ml saline; 40-minute infusion